The landscape of HIV treatment has experienced remarkable transformations over the last four decades. What was once considered a complex, heavily burdened regimen of multiple pills taken several times a day has steadily evolved into streamlined, once-daily single-tablet therapies that help millions of people achieve long-term viral suppression. However, the next monumental leap in HIV care is now on the horizon, aiming to shift the paradigm from daily dosing to long-acting regimens. At the forefront of this evolution is a groundbreaking partnership between pharmaceutical giants Gilead Sciences and Merck & Co.
Recently, the companies unveiled highly anticipated Phase 3 clinical trial results for their investigational once-weekly oral HIV pill. The combination therapy, which merges Merck’s islatravir and Gilead’s lenacapavir into a single tablet, demonstrated exceptional efficacy in suppressing the virus among adults living with HIV. By meeting primary endpoints of non-inferiority compared to standard daily antiretroviral treatments, this novel therapy is poised to become the first once-weekly oral HIV regimen in medical history.
The detailed data, scheduled for presentation at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, Brazil, provide strong clinical evidence supporting the safety and efficacy of the drug. In this comprehensive article, we explore the science behind this innovative treatment, dive deep into the ISLEND-1 and ISLEND-2 trial results, analyze its safety profile, and discuss what a once-weekly pill means for the future of patient adherence and HIV management globally.
The Science and Mechanics of the Once-Weekly HIV Pill
To understand why a once-weekly pill is such a monumental scientific achievement, one must examine the distinct pharmacological properties of the two active ingredients: islatravir and lenacapavir. Both drugs possess unique pharmacokinetic profiles that allow them to remain active in the human body for extended periods, enabling the transition away from daily dosing.
Islatravir: A Next-Generation NRTTI
Developed by Merck, islatravir (formerly MK-8591) belongs to a new class of antiretrovirals known as nucleoside reverse transcriptase translocation inhibitors (NRTTIs). Unlike traditional reverse transcriptase inhibitors that block the virus at a single point during replication, islatravir works through multiple mechanisms to inhibit HIV replication. Its high potency and prolonged half-life in human cells make it an ideal candidate for long-acting treatments.
Lenacapavir: A First-in-Class Capsid Inhibitor
Gilead’s lenacapavir is a revolutionary, first-in-class capsid inhibitor. The HIV capsid is a cone-shaped protein shell that protects the virus’s genetic material. Lenacapavir disrupts the HIV life cycle at multiple distinct stages by interfering with the assembly, disassembly, and transport of the capsid. Because of its multi-stage interference and incredibly slow clearance rate from the body, lenacapavir is already utilized as a long-acting injectable (branded as Sunlenca and Yeztugo).
When combined into a single oral tablet (ISL/LEN), the complementary mechanisms of islatravir and lenacapavir create a formidable barrier against viral replication, effectively preventing the virus from multiplying and keeping the patient’s viral load undetectable for a full week.
Deep Dive into Phase 3 Trial Results: ISLEND-1 and ISLEND-2
The clinical validation for this once-weekly regimen stems from the robust Phase 3 ISLEND clinical program. Both the ISLEND-1 and ISLEND-2 trials evaluated the efficacy and safety of islatravir (2 mg) combined with lenacapavir (300 mg) in adults with HIV who were already virologically suppressed on daily antiretroviral therapy. The primary endpoint for both studies was to determine whether the once-weekly pill was non-inferior—meaning it works at least as well—as established daily treatments at 48 weeks.
ISLEND-1 Trial: Switching from Biktarvy
The ISLEND-1 study was a blinded trial that enrolled 607 participants whose HIV was well-controlled on Biktarvy, Gilead’s blockbuster once-daily single-tablet regimen. Participants were randomly assigned to either switch to the once-weekly ISL/LEN pill or remain on their daily Biktarvy regimen.
The 48-week results were striking. Zero participants (0%) who switched to the once-weekly ISL/LEN regimen experienced virologic failure (defined as having HIV-1 RNA levels reaching 50 copies/mL or higher). In contrast, a mere 0.3% (one individual) in the group that remained on daily Biktarvy reached this threshold. These figures unequivocally confirmed that the weekly treatment is highly efficacious and successfully met its primary endpoint of non-inferiority to one of the most widely used daily HIV drugs on the market.
ISLEND-2 Trial: Switching from Standard-of-Care Regimens
To ensure the drug’s efficacy across a broader population, the open-label ISLEND-2 trial enrolled 626 individuals who were virologically suppressed on various standard-of-care daily oral regimens.
At Week 48, the results similarly demonstrated the robust efficacy of the weekly pill. Only one participant (0.3%) taking the once-weekly ISL/LEN combination showed HIV-1 RNA levels at 50 copies/mL or higher. Among those who continued their standard daily treatments, the rate was slightly higher at 1.3%. Once again, the data affirmed the once-weekly pill’s non-inferiority, providing powerful evidence that patients can safely switch from a variety of daily regimens to this more convenient dosing schedule without risking viral rebound.
Unpacking the Safety Profile and Tolerability
Efficacy is only half the battle in HIV treatment; the medication must also be safe, tolerable, and free of debilitating side effects that could deter a patient from adhering to their regimen. Historically, the clinical development of islatravir faced a temporary setback when early trials using higher doses noted a decline in patients’ total lymphocyte and CD4+ T-cell counts. Consequently, observing these specific immune metrics was a top priority for investigators in the ISLEND program.
Stable CD4+ T-Cell Counts
The Phase 3 data should reassure both patients and clinicians. The dose of islatravir used in the ISL/LEN weekly pill (2 mg) is significantly lower than the doses that previously triggered safety signals. In the ISLEND-1 trial, CD4+ T-cell and lymphocyte counts remained stable in both treatment groups through Week 48, and notably, not a single participant discontinued the trial due to a decrease in these crucial immune cells.
In ISLEND-1, patients on ISL/LEN saw an average change in CD4+ count of minus 10 cells/μL, compared to minus 18 cells/μL in the Biktarvy group—both minor, clinically insignificant fluctuations for individuals starting with healthy baselines of around 740 cells/μL.
General Adverse Events and Side Effects
Overall, the safety profile of the once-weekly ISL/LEN pill was highly comparable to standard daily oral treatments, with no new safety concerns identified. In the blinded ISLEND-1 study, treatment-related adverse events were reported in 13.5% of the participants taking ISL/LEN, virtually identical to the 13.2% seen in the daily Biktarvy group.
The most common side effects reported were mild and typical for antiretroviral therapies, primarily consisting of nausea, headache, and diarrhea. Discontinuation rates due to adverse events were incredibly low—just 2% for the once-weekly pill and 1.7% for Biktarvy—underscoring the drug’s excellent tolerability profile over the course of a year. Furthermore, researchers noted no clinically meaningful difference in body weight changes between the groups, addressing a common concern regarding weight gain associated with modern HIV treatments.
Why a Once-Weekly Regimen Matters: Adherence and Patient Well-Being
The introduction of a once-weekly pill represents more than just a biochemical victory; it holds profound implications for the psychological well-being and daily lives of people living with HIV.
Combating Treatment Fatigue
While daily single-tablet regimens are highly effective, taking a pill every single day for the rest of one’s life requires immense discipline. Treatment fatigue is a well-documented phenomenon. Many individuals struggle with adherence due to busy schedules, travel, changing life circumstances, or the simple human error of forgetting a dose. When doses are missed, the virus has the opportunity to replicate, which can lead to drug resistance and disease progression.
Jared Baeten, Gilead’s clinical development lead in virology, summarized the impact perfectly: “Once-a-week pills take the psychological challenges of HIV adherence from seven days a week to one”. Reducing the dosing frequency mathematically decreases the opportunities for missed doses by over 85%, which could lead to better overall population-level viral suppression.
Easing the Psychological Burden
Beyond the logistics of swallowing a pill, there is a heavy psychological aspect to daily HIV treatment. For many patients, taking a daily pill serves as an inescapable, daily reminder of their chronic illness. It can carry an emotional weight and, in some communities, an ongoing fear of stigma if the daily pill bottles are discovered by roommates, partners, or family members.
Transitioning to a once-weekly pill allows individuals to compartmentalize their treatment. Taking medication just four times a month, rather than thirty times, helps normalize daily life and untethers patients from the constant reminder of their status.
Bridging the Gap Between Daily Pills and Injectables
The field has recently seen the introduction of long-acting injectable HIV therapies (such as cabotegravir/rilpivirine and lenacapavir injections), which can be administered every month or every six months. While injectables are revolutionary, they are not suitable for everyone. They require regular clinic visits, healthcare infrastructure, and some patients have a fear of needles or experience injection-site pain.
The once-weekly ISL/LEN pill sits perfectly in the middle. It offers the reduced dosing frequency of a long-acting treatment while preserving the convenience and autonomy of an oral pill that can be taken in the privacy of one’s own home.
Future Regulatory Filings and Market Impact
With the successful completion of the primary endpoints for ISLEND-1 and ISLEND-2, Gilead and Merck are aggressively moving toward commercialization. The detailed findings are a cornerstone presentation at the 26th International AIDS Conference (AIDS 2026) in Rio de Janeiro, highlighting the drug’s importance to the global infectious disease community.
The companies have officially announced their intention to file the Phase 3 data with global regulatory authorities to seek approval for the ISL/LEN combination. If approved by entities like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), the therapy will shatter the existing paradigm, becoming the first once-weekly oral treatment for HIV.
For Gilead, this represents a strategic expansion of its dominance in the HIV market, fortifying its franchise alongside the industry-leading Biktarvy and its newer, long-acting injectable Yeztugo (lenacapavir). For Merck, this validates the immense potential of islatravir and strengthens its position in infectious diseases. Together, the partnership merges the best of both companies’ pipelines to address a clear, unmet need for patients.
Expanding Global Access
As Gilead prepares for the launch of its lenacapavir-based regimens, the company is also looking at the broader global impact. Alongside the treatment trials, Gilead has expanded its partnerships with the Global Fund and PEPFAR, pledging to increase its no-profit supply program to reach 3 million people through 2028 across sub-Saharan Africa and exploring access pathways in Latin America. While these initiatives currently focus heavily on long-acting preventatives, the infrastructure being built suggests that innovative treatments like the once-weekly pill may eventually reach the communities globally that need them most.
Conclusion
The Phase 3 results of the ISLEND trials mark a historic milestone in the fight against HIV. By demonstrating that a once-weekly oral combination of islatravir and lenacapavir is just as effective and safe as current daily standards, Gilead and Merck have proven that the future of HIV treatment lies in long-acting convenience.
For the millions of individuals living with HIV worldwide, the prospect of managing their condition with a single pill taken just once a week is life-changing. It promises to mitigate the fatigue of daily adherence, reduce the psychological weight of the disease, and offer a powerful new tool in the ongoing global effort to end the HIV epidemic. As the medical community awaits formal regulatory approvals, one thing is abundantly clear: the standard of HIV care is poised for a revolutionary, long-awaited upgrade.
Read more fitness updates here
